MiNK Therapeutics, Inc. (INKT): R&D Expense
$5.76M
Year ended 2025-12-31
$5.75M
Trailing 12 months to 2026-06-30
-37.1%
3-year compound annual growth
-9.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.76M | -9.1% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $6.34M | -59.1% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $15.49M | -33.0% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $23.12M | +65.5% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $13.97M | +46.9% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $9.51M | n/a | 2022-03-18, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | 2025-12-31 | $5.76M | -9.1% |
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $6.79M | -35.4% |
| BioAtla, Inc. (BCAB) | 2025-12-31 | $43.57M | -30.9% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $6.00M | +33.5% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $27.18M | -34.9% |
| Curis Inc (CRIS) | 2025-12-31 | $28.25M | -26.7% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
Compare INKT, INTS, BCAB, ENTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗